Lior Arazi

This inventor holds 16 USPTO granted patents and 20 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Alpha Tau Medical Ltd., Althera Medical Ltd., Tel Aviv University. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lior Arazi. Retrieved from https://idiyas.com/inventor/lior-arazi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 20)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 52(Granted Patents)

Company Filing History:

14 out of 24

Alpha Tau Medical Ltd.

Years Active: 2014-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12434073 - Diffusing alpha-emitter radiation therapy for prostate cancer (2025-10-07),

2. 12246191 - Diffusing alpha-emitter radiation therapy with enhanced beta treatment (2025-03-11),

3. 12076583 - Diffusing alpha-emitter radiation therapy for melanoma (2024-09-03),

4. 12076582 - Diffusing alpha-emitter radiation therapy for colorectal cancer (2024-09-03),

5. 12076581 - Diffusing alpha-emitter radiation therapy for glioblastoma (2024-09-03),

6. 12070621 - Diffusing alpha-emitter radiation therapy for pancreatic cancer (2024-08-27),

7. 12070620 - Activity levels for diffusing alpha-emitter radiation therapy (2024-08-27),

8. 12064643 - Diffusing alpha-emitter radiation therapy for breast cancer (2024-08-20),

9. 12042668 - Diffusing alpha-emitter radiation therapy for squamous cell carcinoma (2024-07-23),

10. 11964168 - Diffusing alpha-emitter radiation therapy for prostate cancer (2024-04-23),

11. 11857803 - Diffusing alpha-emitter radiation therapy with enhanced beta treatment (2024-01-02),

12. 11666782 - Treatment planning for alpha particle radiotherapy (2023-06-06),

13. 11666781 - Treatment planning for alpha particle radiotherapy (2023-06-06),

14. 10058713 - Method and device for radiotherapy (2018-08-28),

15. 8894969 - Method and device for radiotherapy (2014-11-25),

Title: Lior Arazi: Innovator in Radiation Therapy

Introduction

Lior Arazi is a prominent inventor based in Tel Aviv, Israel, known for his significant contributions to the field of radiation therapy. With a total of 16 patents to his name, Arazi has made remarkable advancements in the treatment of prostate cancer through innovative methods.

Latest Patents

Among his latest patents is a method for treating prostate cancer tumors using diffusing alpha-emitter radiation therapy (DaRT). This method involves identifying a tumor as a prostate cancer tumor and implanting at least one DaRT source with a suitable radon release rate for a specified duration. The goal is to achieve a cumulated activity of released radon between 7 Mega becquerel (MBq) hour and 14.7 MBq hour per centimeter length. Each DaRT source is strategically placed less than 3.9 millimeters apart from adjacent sources. Another notable patent focuses on enhancing beta treatment through an interstitial source that includes a base suitable for tumor implantation. This source contains radioactive atoms that emit beta radiation, achieving a significant dose at a distance of 2 millimeters from the base.

Career Highlights

Lior Arazi has worked with notable companies such as Alpha Tau Medical Ltd. and Ramot at Tel Aviv University Ltd. His work has been instrumental in developing innovative therapies that improve patient outcomes in cancer treatment.

Collaborations

Arazi has collaborated with esteemed colleagues, including Itzhak Kelson and Amnon Gat, contributing to the advancement of radiation therapy technologies.

Conclusion

Lior Arazi's innovative work in radiation therapy exemplifies the impact of dedicated inventors in the medical field. His patents and collaborations continue to pave the way for new treatment options for prostate cancer.

Profile summary based on public USPTO records.